Clinical trial · Observational
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
A Non-interventional Multicenter Study of First-line Avastin® (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT01266564CI-TRIAL-00029049completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study will assess the progression-free survival, overall response and safety of Avastin (bevacizumab) in combination with chemotherapy in a real life setting in patients with metastatic colorectal cancer. Data will be collected from patients for approximately 2 years.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort
Primary outcomes (1)
- measure
- Progression-free survival in a real life setting assessed by computer tomography
- timeFrame
- Approximately 2 years
Secondary outcomes (5)
- measure
- Overall response rate assessed by computer tomography
- timeFrame
- Approximately 2 years
- measure
- Response of Avastin according to the sites of metastases assessed by computer tomography
- timeFrame
- Approximately 2 years
- measure
- Chemotherapy regimens used in combination with Avastin
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients, age \>/=18 years * Proven metastatic colorectal carcinoma * Patients have measurable disease * Patients are eligible to receive first-line Avastin * Patients have signed data release form Exclusion Criteria: * Contra-indication to receive Avastin according to the local labeling * Participation in a clinical study within 30 days prior to enrolment * Patients have any other primary cancer * Concomitant treatment with other biologics * History of other malignant disease in the past 5 years except basal cell carcinoma
References
Publications (0)
Data not yet available
No reference posted for this study.